Satish Chandrashekaran1, Stacy A Crow Pharm2,3, Sadia Z Shah4, Chris J Arendt Pharm2,3, Cassie C Kennedy3,5. 1. Division of Pulmonary, Critical Care and Sleep Medicine, Lung Transplantation Program, University of Florida Gainesville, FL. 2. Pharmacy Services, Mayo Clinic, Rochester, MN. 3. William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN. 4. Division of Pulmonary and Critical Care Medicine, Mayo Arizona. 5. Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN.
Abstract
PURPOSE OF THE REVIEW: The number of lung transplantations performed worldwide continues to increase. There is a growing need in these patients for more effective immunosuppressive medications with less toxicity. RECENT FINDINGS: This review article summarizes the recent studies and developments in lung transplant immunosuppression. Novel immunosuppressive medications and strategies used in other solid organ transplantations are being trialed in lung transplantation. This includes the use of co-stimulation blockers like belatacept and mTOR inhibitors like everolimus. Calcineurin sparing regimens have been described in an attempt to minimize nephrotoxicity. Assays to measure the bioactivity of immunosuppressive medications to determine the global immune competence, such as Immuknow assay and Gamma interferon response are gaining traction. SUMMARY: Immunosuppression in lung transplant is evolving with the development of newer drugs and promising strategies to optimize immunosuppression. Further studies with multicenter randomized trials are required to increase the strength of the evidence.
PURPOSE OF THE REVIEW: The number of lung transplantations performed worldwide continues to increase. There is a growing need in these patients for more effective immunosuppressive medications with less toxicity. RECENT FINDINGS: This review article summarizes the recent studies and developments in lung transplant immunosuppression. Novel immunosuppressive medications and strategies used in other solid organ transplantations are being trialed in lung transplantation. This includes the use of co-stimulation blockers like belatacept and mTOR inhibitors like everolimus. Calcineurin sparing regimens have been described in an attempt to minimize nephrotoxicity. Assays to measure the bioactivity of immunosuppressive medications to determine the global immune competence, such as Immuknow assay and Gamma interferon response are gaining traction. SUMMARY: Immunosuppression in lung transplant is evolving with the development of newer drugs and promising strategies to optimize immunosuppression. Further studies with multicenter randomized trials are required to increase the strength of the evidence.
Entities:
Keywords:
Lung transplantation; calcineurin-sparing regimens; global immune competence; immunosuppression
Authors: G I Snell; V G Valentine; P Vitulo; A R Glanville; D C McGiffin; J E Loyd; A Roman; R Aris; A Sole; A Hmissi; U Pirron Journal: Am J Transplant Date: 2006-01 Impact factor: 8.086
Authors: A Zuckermann; W Klepetko; T Birsan; S Taghavi; O Artemiou; W Wisser; G Dekan; E Wolner Journal: J Heart Lung Transplant Date: 1999-05 Impact factor: 10.247
Authors: Richard J Kowalski; Diane R Post; Roslyn B Mannon; Anthony Sebastian; Harlan I Wright; Gary Sigle; James Burdick; Kareem Abu Elmagd; Adriana Zeevi; Mayra Lopez-Cepero; John A Daller; H Albin Gritsch; Elaine F Reed; Johann Jonsson; Douglas Hawkins; Judith A Britz Journal: Transplantation Date: 2006-09-15 Impact factor: 4.939
Authors: Flavio Vincenti; Christian Larsen; Antoine Durrbach; Thomas Wekerle; Björn Nashan; Gilles Blancho; Philippe Lang; Josep Grinyo; Philip F Halloran; Kim Solez; David Hagerty; Elliott Levy; Wenjiong Zhou; Kannan Natarajan; Bernard Charpentier Journal: N Engl J Med Date: 2005-08-25 Impact factor: 91.245
Authors: Aldo T Iacono; Bruce A Johnson; Wayne F Grgurich; J Georges Youssef; Timothy E Corcoran; Deidre A Seiler; James H Dauber; Gerald C Smaldone; Adriana Zeevi; Samuel A Yousem; John J Fung; Gilbert J Burckart; Kenneth R McCurry; Bartley P Griffith Journal: N Engl J Med Date: 2006-01-12 Impact factor: 91.245
Authors: R Wiesner; J Rabkin; G Klintmalm; S McDiarmid; A Langnas; J Punch; P McMaster; M Kalayoglu; G Levy; R Freeman; H Bismuth; P Neuhaus; R Mamelok; W Wang Journal: Liver Transpl Date: 2001-05 Impact factor: 5.799
Authors: Keith McNeil; Allan R Glanville; Thorsten Wahlers; Christiane Knoop; Rudolf Speich; Richard D Mamelok; Joerg Maurer; Jane Ives; Paul A Corris Journal: Transplantation Date: 2006-04-15 Impact factor: 4.939
Authors: Melissa B King-Biggs; Jordan M Dunitz; Soon J Park; S Kay Savik; Marshall I Hertz Journal: Transplantation Date: 2003-05-15 Impact factor: 4.939